Stem Cells Archives | Page 103 of 201

Synthego Launches High-Throughput Induced Pluripotent Stem Cell Genome Engineering

November 5, 2019 By Cade Hildreth, Founder & President Leave a Comment

National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer’s, Stem cell pioneer Bill Skarnes joins advisory board

REDWOOD CITY, Calif., Oct. 22, 2019 — Synthego, the leading genome engineering company, announced the launch of genome engineering for induced pluripotent stem (iPS) cells. The new offering expands Synthego’s automated cell editing to achieve unprecedented editing efficiency of iPS cells at an industrial scale. [Read more…]

Will I See You at Phacilitate Leaders World 2020 (Psst, Get 10% Off)

November 1, 2019 By Cade Hildreth, Founder & President 2 Comments

Advanced therapy companies have been rapidly populating over the past few years, making it a high-value, fast-growth industry. Key drivers include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for advanced therapies to revolutionize healthcare.

Stem Cell Industry Growth

Stem cell treatments are one of several segments that compose the advanced therapies industry, which includes but is not limited to cell therapy, gene therapy, and tissue engineering applications.

Stem cells have gained tremendous momentum over the last decade. As of November 2019, stem cell scientific publications have reached over 364,930 worldwide, with 25,000+ now being published per year.

For stem cell clinical trials, 7,400+ have been registered on ClinicalTrials.gov. Because this registry includes approximately 3/4ths of clinical trials worldwide, the total number of stem cell clinical trials worldwide is estimated to be approaching 10,000.

[Read more…]

Platelet BioGenesis Bags $56M to Develop Human iPSC-Derived Platelets as Nuclear Countermeasure

October 10, 2019 By Cade Hildreth, Founder & President 1 Comment

Highlights:

Platelet BioGenesis has the world’s first technology to generate clinical-grade human platelets from induced pluripotent stem cells (iPSCs).
Platelet BioGenesis has been awarded $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop donor-independent platelets as a treatment for radiological and nuclear exposure.

[Read more…]

Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

October 9, 2019 By Cade Hildreth, Founder & President Leave a Comment

State-of-the-Art Facility Designed to use Clonal Master iPSC Lines as Renewable Cell Source for Manufacture of Off-the-Shelf Product Pipeline

SAN DIEGO, Sept. 30, 2019 — Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has opened its current Good Manufacturing Process (cGMP) compliant manufacturing facility for the clinical production of its off-the-shelf natural killer (NK) cell and chimeric antigen receptor (CAR) T-cell product candidates. [Read more…]

SanBio Awarded RMAT for SB623, a Modified Stem Cell Treatment for TBI

September 20, 2019 By Cade Hildreth, Founder & President 1 Comment

SanBio, a company developing regenerative cell medicines for neurological disorders, has been awarded a regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for SB623.

SB623 is a cell therapy that the company has developed for the treatment of chronic neurological motor deficits that occur as a result of traumatic brain injury (TBI). In addition to this treatment, SanBio is developing regenerative therapies for stroke, diseases of the eye, Parkinson’s disease (PD), and other neurological conditions. [Read more…]